Aurobindo Pharma is currently trading at Rs. 788.65, up by 3.50 points or 0.45% from its previous closing of Rs. 785.15 on the BSE.
The scrip opened at Rs. 775.45 and has touched a high and low of Rs. 791.40 and Rs. 775.45 respectively. So far 26313 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 791.85 on 24-Jul-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.
Last one week high and low of the scrip stood at Rs. 791.85 and Rs. 746.50 respectively. The current market cap of the company is Rs. 45987.39 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.86% and 8.31% respectively.
Aurobindo Pharma’s wholly owned subsidiary — Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mozobil Injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation. The product is being launched in July FY24. The approved product has an estimated market size of around $210 million for the twelve months ending May 2023, according to IQVIA.
This is the 163rd ANDA (including 8 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products. Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.